PRPH, US74345W2070

ProPhase Labs stock: Shyam Venkatesan reports 5.50 percent stake in ProPhase Labs stock

Published on 10/23/2026 at 05:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A filing lists 855,101.98 shares on October 16, 2026. ProPhase Labs stock had USD 1.01 million in second-quarter sales and a USD 0.22 per-share loss.

Ownership and operating scale

A Schedule 13G dated October 16, 2026 listed 855,101.98 shares and 5.50 percent ownership.
Second-quarter sales reached USD 1.01 million versus USD 1.25 million a year earlier, while the per-share loss narrowed to USD 0.22.
ProPhase Labs had a USD 0.1 million market capitalization as of October 22, 2026.

PRPH, US74345W2070, Illustration mit AI erstellt.

ProPhase Labs (ISIN US74345W2070) is tied to an ownership filing listing 855,101.98 shares, or 5.50 percent of the company, as of October 16, 2026, according to the SEC. The filing identifies Shyam Venkatesan as the reporting person and gives the ownership disclosure a concrete place in the latest ProPhase Labs news flow.

Three dated developments

On June 30, 2026, ProPhase Labs reported second-quarter sales of USD 1.01 million, down from USD 1.25 million a year earlier, while the per-share loss narrowed from USD 1.08 to USD 0.22, according to Benzinga. On October 13, 2026, a New Jersey judge granted interim approval for ProPhase units to seek votes on a Chapter 11 plan after a USD 25.00 million claim, Law360 reported. On October 16, 2026, Venkatesan reported sole voting power over 855,101.98 shares, equal to 5.50 percent of the class, in the SEC filing.

What does the filing mean?

The ownership disclosure is material because it quantifies a shareholder position while the company works through a mixed operating and legal picture. The SEC filing says the securities were not acquired to change or influence control, except for activities connected with a nomination under the applicable rule. That language distinguishes a disclosed stake from a stated takeover proposal.

The financial comparison is more cautious. Second-quarter sales of USD 1.01 million were 18.85 percent below the USD 1.25 million reported for the comparable period, even as the per-share loss improved by USD 0.86. The figures show why the ownership filing does not by itself resolve the question of operating recovery.

Scale remains the key measure

ProPhase Labs describes itself as a biotech, genomics and consumer-products company developing whole-genome sequencing, diagnostic products and over-the-counter supplements, according to its investor-relations page. Market capitalization stood at USD 0.1 million on October 22, 2026, leaving the reported 5.50 percent position as a small absolute market value despite its clear disclosure significance.